Neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT 'basket' trial Meeting Abstract
| Authors: | Wildiers, H.; Boni, V.; Saura, C.; Oliveira, M.; Jhaveri, K.; Won, H.; Bidard, F. C.; Brufsky, A. M.; Burkard, M. E.; Cervantes, A.; Fernández-Martos, C.; Haley, B.; Loi, S.; Spanggaard, I.; Panni, S.; Lu, J.; Dujka, M. E.; Xu, F.; Macia, S.; Eli, L. D.; Lalani, A. S.; Piha-Paul, S.; Meric-Bernstam, F.; Solit, D. B.; Hyman, D. M. |
| Abstract Title: | Neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT 'basket' trial |
| Meeting Title: | 42nd Annual San Antonio Breast Cancer Symposium (SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 80 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2019 Dec 10-14 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2020-02-01 |
| Language: | English |
| ACCESSION: | WOS:000527012500329 |
| DOI: | 10.1158/1538-7445.Sabcs19-p1-19-08 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: P1-19-08 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work